(CDAX, Industrial Goods & Services, FPH GR)



Buy		Value Indicators: DCF:		Warburg ESG Risk Score: ESG Score (MSCI based): Balance Sheet Score:	2.4 3.0 4.3	Manufacturer of franking ma	
EUR 5.00	(EUR 4.80)			Market Liquidity Score:	0.0	and provider of mail services	š.
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2021e
		Market cap:	48.5	Freefloat	50.7 %	Beta:	1.6
Price	EUR 3.14	No. of shares (m):	15.5	Obotritia Capital	28.0 %	Price / Book:	4.1 x
Upside	59.2 %	EV:	80.5	Active Ownership Fund	9.5 %	Equity Ratio:	7 %
		Freefloat MC:	24.6	SALTARAX GmbH	5.0 %	Net Fin. Debt / EBITDA:	0.7 x
		Ø Trad. Vol. (30d):	12.28 th			Net Debt / EBITDA:	2.0 x

Continued improvement

Stated Figures	s Q3/2021	:						Comment on Figures:
in EUR m	Q3/21	Q3/21e	Q3/20	уоу	9M/21	9M/20	уоу	• Francotyp Postalia Holding AG (FP) on Thursday (18.11.21) presented
Sales	49.3	48.3	47.9	3.1%	148.9	147.6	0.9%	 the figures for the third quarter and the first nine months of 2021. These figures exceeded expectations and showed further progress in
EBITDA	6.4	6.0	5.9	9.0%	15.2	19.5	-21.9%	the transformation process.
margin	12.9%	12.4%	12.2%		10.2%	13.2%		
EPS in EUR	0.10	0.05	-0.01	-	0.14	0.10	40.0%	
	0.10	5.05	0.01	- 1	0.14	5.10	40.070	


The figures presented showed robust development in all areas. Sales in the Software & BPA and IoT division recorded sales growth of 8.3% to EUR 13.2m (12.2). Especially in the area of input management, the solution portfolio was expanded and new customers were won. In addition, the FP Sign signature solution continued to show positive business development, which can be attributed to sales success and the further development of the products. Revenue in the Mail Services division (collection, franking and consolidation of business mail) rose to EUR 45.6 (42.9) + 6.4%. Sales in the most important Franking & Office Solutions division remained stable, adjusted for currency effects (-2.6% to EUR 90.1m vs. EUR 92.5m, including a negative currency effect of EUR 2.1m). The solutions from HEFTER Systemform, which was taken over in 2020, e.g. with air filter systems or high-security shredders, have made a positive contribution to sales, together with recurring sales in the franking area.

Flanked by this operational development, the cost side continued to benefit from the implementation of the FUTURE @ FP transformation programme. Together with the introduction of a new ERP / CRM system, further cost reductions are possible in 2022.

On the basis of slightly adjusted forecasts / rollover, the share continues to be rated Buy with a price target of EUR 5.00 (4.80).

Changes in E	stimates:						Comment on Changes:
FY End: 31.12. in EUR m	2021e (old)	+ / -	2022e (old)	+ / -	2023e (old)	+ / -	 The figures presented provide the basis for somewhat higher expectations for the coming periods. EBITDA includes slightly higher
Sales	198.0	1.0 %	203.9	1.0 %	210.1	1.0 %	costs for the transformation programme than originally expected (WRe
EBITDA	15.8	1.0 %	27.5	-2.7 %	30.5	-2.5 %	• On the bottom line, there is also lower depreciation and a better finance
EBIT	-3.7	n.m.	8.0	3.1 %	11.0	2.3 %	result than initially expected (WRe).
EPS	-0.16	n.m.	0.33	12.1 %	0.45	8.9 %	

37.9	4.25	narmy in	FY End: 31.12. in EUR m	CAGR (20-23e)	2017	2018	2019	2020	2021e	2022e	2023e
35 Gross profit margin 55.6 % 57.0 % 60.3 % 55.8 % 52.0 % 55.5 % 55.5 % 55.5 % 325 Gross profit margin 55.2 % 26.3 17.1 33.3 8.0 16.0 26.8 22.3 325 Gross profit margin 55.2 % 26.3 17.1 33.3 8.0 16.0 26.8 22.4 326 Gross profit margin 55.2 % 26.3 17.1 33.3 8.0 16.0 26.8 22.5 8.3 14.8 3275 Gross profit margin 3.5 % -0.1 % 2.8 % -7.1 % -1.3 % 4.0 % 5.5 Margin 3.5 % -0.0 % 0.6 0.11 -0.94 -0.07 0.37 0.07 Net income - 0.29 0.06 0.11 -0.94 -0.07 0.37 0.03 1 month: 1.7 % 6.5 % 0.5 % 0.4 % 0.8 % 0.9 % n.a. n.a. n.a. 1.7 % 0.33 0.00 0.00 0.15 0.03 0.03 0.03 0.03 0.03	4 - Whyter "	*V. V\ ₄ /2		2.7 %							212.2
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	3.75 - MM										3.0 %
$\begin{array}{c c c c c c c c c c c c c c c c c c c $. N '		, ,								55.5 %
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	3.5			55.2 %							29.7
3 3 3 5% -0.1% 2.8% -7.1% -1.3% 4.0% 5. 01/21 03/21 05/21 07/21 09/21 11/21 6.0 1.7 -15.2 -1.2 6.0 6.0 Performance vs CDAX: 1 month: 1.7% 0.29 0.06 0.11 -0.94 -0.07 0.37 0.00 DPS - 0.12 0.03 0.03 0.00 0.00 0.15 0.00 Dividend Yield 2.3% 0.8% 0.9% n.a. n.a. n.a. 4.7% 6.5 FCF / Market cap 0.36 0.38 0.17 0.86 -0.03 0.31 0.00 FCF / Market cap 0.5 x 0.4 x 0.5 x 0.4 x	3.25 - Man MAN A	6 m .									14.0 %
2.75	which has which "	Vichman 1		-							11.2
2/3 01/21 03/21 06/21 01/21 01/21 06/21 01/21 06/21 01/21 06/21 01/21 06/21 01/21 06/21 01/21 06/21 01/21 06/21 01/21 06/21 01/21 06/21 01/21 06/21 01/21 00/21 01/21 00/21 0	31 IN	MAN WIT									5.3 %
Unit user user User user<	2.75 -	M.	Net income	-	4.6	0.9	1.7	-15.2	-1.2	6.0	7.9
Francodyp-postalia holding — CDAX (normalised) EPS adj. DPS - 0.29 0.06 0.11 -0.04 -0.07 0.37 0.00 Rel. Performance vs CDAX: 1 month: 1.7 % 0.12 0.03 0.00 0.00 0.15 0.00 6 months: 8.5 % 0.8 % 0.9 % n.a. n.a. n.a. 4.7 % 6.3 Year to date: -16.3 % 8.5 % 0.9 % 0.11 5.0 % 26.3 % -1.1 % 10.0 % 7.7 FCF/Market cap 0.5 x 0.4 x 0.5 x 0.4 x	01/21 03/21 05/21 07/	21 09/21 11/21	EPS	-	0.29	0.06	0.11	-0.94	-0.07	0.37	0.49
BPS - 0.12 0.03 0.03 0.00 0.015 0.00 1 month: 1.7 % 6 months: 8.5 % Year to date: -16.3 % Trailing 12 months: -32.1 % EV / EBITDA 4.2 x 5.0 x 2.9 x 0.4 x 0.4 x 0.4 x 0.4 x 0.4 x 0.03 0.00 0.015 0.6 c Company events: -16.3 % -17 % 62.6 x 31.5 x n.a. n.a. 4.7 % 6.5 x P / E 10.1 % 5.0 % 26.3 % -1.1 % 10.0 % 7.7 % Company events: -16.3 % -16.3 % 0.5 x 0.4 x 0.5 x 0.4 x 0			EPS adj.	-	0.29	0.06	0.11	-0.94	-0.07	0.37	0.49
FCFPS 0.36 0.38 0.17 0.86 -0.03 0.31 0.06 6 months: 8.5 % Year to date: -16.3 % Trailing 12 months: -32.1 % EV / Sales 0.5 x 0.4 x 0.5 x 0.4 x 0.4 x 0.4 x 0.4 x Company events: -16.3 % EV / EBITDA 4.2 x 5.0 x 2.9 x 10.6 x 5.2 x 2.9	mancotyp-postalia holding — C	DAX (normalised)	DPS	-	0.12	0.03	0.03	0.00	0.00	0.15	0.20
1 month: 1.7 % FCFPS 0.36 0.38 0.17 0.86 -0.03 0.31 0.00 6 months: 8.5 % FCF / Market cap 6.9 % 10.1 % 5.0 % 26.3 % -1.1 % 10.0 % 7.7 6 months: 8.5 % FCF / Market cap 0.5 x 0.4 x 0.5 x 0.4 x 0.4 x 0.4 x 0.4 x 0.0 % 7.7 Year to date: -16.3 % EV / Sales 0.5 x 0.4 x 0.5 x 0.4 x	Rel. Performance vs CI	DAX:	Dividend Yield		2.3 %	0.8 %	0.9 %	n.a.	n.a.	4.7 %	6.2 %
6 months: 8.5% Year to date: -16.3% Trailing 12 months: -32.1% Company events: -32.1% FCF Potential Yield 17.9x 62.6x 31.5x 0.4x			FCFPS								0.24
Year to date: -16.3 % EV / Sales 0.5 x 0.4 x 0.5 x 0.4 x			FCF / Market cap		6.9 %	10.1 %	5.0 %	26.3 %	-1.1 %	10.0 %	7.7 %
Trailing 12 months: -32.1 % EV / EBIT 15.1 x n.a. 16.3 x n.a. n.a. 9.4 x 6 Company events: F/E 17.9 x 62.6 x 31.5 x n.a. n.a. 9.4 x 6 FCF Potential Yield 17.9 x 62.6 x 31.5 x n.a. n.a. 8.5 x 6 Net Debt 25.2 24.6 40.3 31.4 31.9 26.9 22			EV / Sales		0.5 x	0.4 x	0.5 x	0.4 x	0.4 x	0.4 x	0.4 x
Company events: P / E 17.9 x 62.6 x 31.5 x n.a. n.a. 8.5 x 6 FCF Potential Yield 17.9 x 62.6 x 31.5 x n.a. n.a. 8.5 x 6 Net Debt 25.2 24.6 40.3 31.4 31.9 26.9 22	Year to date:	-16.3 %	EV / EBITDA		4.2 x	5.0 x	2.9 x	10.6 x	5.2 x	2.9 x	2.6 x
P / E 17.9 x 62.6 x 31.5 x n.a. n.a. 8.5 x 66 Company events: P / E adj. 17.9 x 62.6 x 31.5 x n.a. n.a. 8.5 x 66 FCF Potential Yield 11.2 % 2.2 % 10.0 % -1.3 % 11.8 % 21.9 % 24.4 Net Debt 25.2 24.6 40.3 31.4 31.9 26.9 22	Trailing 12 months:	-32.1 %	EV / EBIT		15.1 x	n.a.	16.3 x	n.a.	n.a.	9.4 x	6.8 x
FCF Potential Yield 11.2 % 2.2 % 10.0 % -1.3 % 11.8 % 21.9 % 24.9 Net Debt 25.2 24.6 40.3 31.4 31.9 26.9 22	5		P/E					n.a.	n.a.		6.4 x
Net Debt 25.2 24.6 40.3 31.4 31.9 26.9 22	Company events:										6.4 x
			FCF Potential Yield		11.2 %	2.2 %	10.0 %	-1.3 %	11.8 %	21.9 %	24.8 %
ROCE (NOPAT) 7.7 % n.a. 2.6 % n.a. n.a. 12.6 % 16.			Net Debt		25.2	24.6	40.3	31.4	31.9	26.9	25.1
			ROCE (NOPAT)		7.7 %	n.a.	2.6 %	n.a.	n.a.	12.6 %	16.2 %
Guidance: Revenues EUR 198-201m, EBITDA EUR 17-18m (2021)			Guidance: F	Revenues EU	R 198-201m,	EBITDA EU	R 17-18m (2	021)			



WARBURG


RESEARCH

Company Background

- Francotyp Postalia Holding AG, headquarted in Berlin, is a globally-active supplier of products and services for the postal market.
- The company was formed in 1983 with the merger of Francotyp (founded 1923) and Postalia (founded 1938) and has thus more than 80 years of experience in the postal market.
- Franking and inserting machines are still the core business activity.
- With new solutions e.g. In the field of IoT and electronic signature, the company strategically expanded its portfolio.

Competitive Quality

- Focusing on customers with low to medium postal needs, Francotyp Postalia caters for two stable segments in the generally difficult market for franking machines.
- The 45% market share in the German market for franking machines demonstrates its reputation as the market leader in Germany based on the following distinguishing characteristics:
- established customer relationships and 80 years of experience in the German market with knowledge of customer demands and an
 efficient service network with rapid reaction times.
- The high proportion (about three-quarters) of recurring revenues as a share of total revenue underlines the successful transformation
 of the competitive quality into a high company quality.
- For new market entrants, Francotyp Postalia's existing customer base is an unachievable target and the franking machines niche is unattractive.



COMMENT Published 22.11.2021 2

DOF



	Detaile	d forecas	t period				Т	ransition	al period					Term. Value
Figures in EUR m	2021e	2022e	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	
Sales	200.0	206.0	212.2	218.5	225.1	231.9	238.8	246.0	253.4	261.0	268.8	276.8	285.2	
Sales change	2.1 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	1.0 %
EBIT	-2.5	8.3	11.2	13.1	13.5	13.9	14.3	14.8	15.2	15.7	16.1	16.6	17.1	
EBIT-margin	-1.3 %	4.0 %	5.3 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	6.0 %	
Tax rate (EBT)	32.0 %	32.0 %	32.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	
NOPAT	-1.7	5.6	7.6	8.8	9.0	9.3	9.6	9.9	10.2	10.5	10.8	11.1	11.5	
Depreciation	18.5	18.5	18.5	19.7	20.3	18.5	19.1	17.2	17.7	18.3	18.8	19.4	20.0	
in % of Sales	9.3 %	9.0 %	8.7 %	9.0 %	9.0 %	8.0 %	8.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	
Changes in provisions	0.0	0.0	0.0	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	
Change in Liquidity from														
- Working Capital	-0.1	0.5	0.5	0.5	0.5	0.5	0.5	0.6	0.6	0.6	0.6	0.6	0.6	
- Capex	20.0	21.0	24.0	24.0	22.5	20.9	16.7	17.2	17.7	18.3	18.8	19.4	20.0	
Capex in % of Sales	10.0 %	10.2 %	11.3 %	11.0 %	10.0 %	9.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	-3.1	2.7	1.6	4.1	6.5	6.6	11.6	9.5	9.8	10.0	10.3	10.6	10.9	13
PV of FCF	-3.1	2.4	1.4	3.2	4.6	4.4	7.0	5.3	5.0	4.7	4.5	4.2	4.0	60
share of PVs		0.70 %						43.41	%					55.89 %
Model parameter							Valuati	on (m)						
Derivation of WACC:			Derivation	of Beta:			Presen	t values 20)33e	4	-8			
							Termin	al Value		6	0			
Debt ratio	20.00 %		Financial S	Strength		1.60	Financi	al liabilities	6	4	7			
Cost of debt (after tax)	2.1 %		Liquidity (s	hare)		1.60	Pensio	n liabilities		2	1			
Market return	7.00 %		Cyclicality			1.60	Hybrid	capital			0			
Risk free rate	1.50 %		Transpare	псу		1.60	Minority	/ interest			0			
			Others			1.60		val. of inve	estments		0		<i>.</i> .	. – –
							Liquidit	,				No. of sha		15.5
WACC	8.66 %		Beta			1.60	Equity	Value		7	6	Value per	share (E	UR) 4.94

Sensitivity Value per Share (EUR)

		Terminal	Growth								Delta EBIT	-margin					
Beta	WACC	0.25 %	0.50 %	0.75 %	1.00 %	1.25 %	1.50 %	1.75 %	Beta	WACC	-1.5 pp	-1 .0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.83	9.7 %	3.68	3.76	3.84	3.93	4.02	4.11	4.22	1.83	9.7 %	2.05	2.67	3.30	3.93	4.55	5.18	5.80
1.71	9.2 %	4.11	4.20	4.30	4.40	4.51	4.63	4.75	1.71	9.2 %	2.41	3.07	3.74	4.40	5.06	5.73	6.39
1.66	8.9 %	4.34	4.44	4.55	4.66	4.78	4.91	5.05	1.66	8.9 %	2.61	3.29	3.98	4.66	5.35	6.03	6.71
1.60	8.7 %	4.59	4.70	4.82	4.94	5.07	5.21	5.36	1.60	8.7 %	2.82	3.53	4.24	4.94	5.65	6.35	7.06
1.54	8.4 %	4.86	4.98	5.11	5.24	5.39	5.54	5.71	1.54	8.4 %	3.05	3.78	4.51	5.24	5.97	6.70	7.43
1.49	8.2 %	5.14	5.27	5.41	5.56	5.72	5.89	6.08	1.49	8.2 %	3.30	4.05	4.81	5.56	6.32	7.07	7.82
1.37	7.7 %	5.77	5.93	6.10	6.28	6.48	6.69	6.92	1.37	7.7 %	3.85	4.66	5.47	6.28	7.09	7.90	8.71

• Francotyp generates high steady cash flows in a normal business year.



Valuation							
	2017	2018	2019	2020	2021e	2022e	2023e
Price / Book	2.5 x	1.8 x	1.7 x	3.9 x	4.1 x	2.8 x	2.1 x
Book value per share ex intangibles	-0.09	-0.46	-0.42	-1.60	-1.98	-1.92	-2.01
EV / Sales	0.5 x	0.4 x	0.5 x	0.4 x	0.4 x	0.4 x	0.4 x
EV / EBITDA	4.2 x	5.0 x	2.9 x	10.6 x	5.2 x	2.9 x	2.6 x
EV / EBIT	15.1 x	n.a.	16.3 x	n.a.	n.a.	9.4 x	6.8 x
EV / EBIT adj.*	15.1 x	n.a.	16.3 x	n.a.	n.a.	9.4 x	6.8 x
P / FCF	14.6 x	9.9 x	20.1 x	3.8 x	n.a.	10.0 x	13.0 x
P/E	17.9 x	62.6 x	31.5 x	n.a.	n.a.	8.5 x	6.4 x
P / E adj.*	17.9 x	62.6 x	31.5 x	n.a.	n.a.	8.5 x	6.4 x
Dividend Yield	2.3 %	0.8 %	0.9 %	n.a.	n.a.	4.7 %	6.2 %
FCF Potential Yield (on market EV)	11.2 %	2.2 %	10.0 %	-1.3 %	11.8 %	21.9 %	24.8 %
*Adjustments made for: -							

Consolidated profit & loss




In EUR m	2017	2018	2019	2020	2021e	2022e	2023e
Sales	206.3	204.2	209.1	195.9	200.0	206.0	212.2
Change Sales yoy	1.7 %	-1.0 %	2.4 %	-6.3 %	2.1 %	3.0 %	3.0 %
Increase / decrease in inventory	0.5	-0.3	0.0	-0.4	0.0	0.0	0.0
Own work capitalised	10.8	14.1	18.6	7.8	6.0	6.2	6.4
Total Sales	217.7	218.0	227.6	203.2	206.0	212.2	218.5
Material expenses	102.9	101.6	101.6	93.9	102.0	97.9	100.8
Gross profit	114.8	116.3	126.0	109.3	104.0	114.3	117.8
Gross profit margin	55.6 %	57.0 %	60.3 %	55.8 %	52.0 %	55.5 %	55.5 %
Personnel expenses	59.2	64.7	60.2	67.8	58.0	58.7	60.5
Other operating income	4.8	1.9	2.9	4.5	2.0	2.1	2.1
Other operating expenses	34.1	36.4	35.4	36.8	32.0	30.9	29.7
Unfrequent items	0.0	0.0	0.0	-1.2	0.0	0.0	0.0
EBITDA	26.3	17.1	33.3	8.0	16.0	26.8	29.7
Margin	12.8 %	8.4 %	15.9 %	4.1 %	8.0 %	13.0 %	14.0 %
Depreciation of fixed assets	19.1	17.3	24.7	18.9	18.5	18.5	18.5
EBITA	7.3	-0.3	8.6	-11.0	-2.5	8.3	11.2
Amortisation of intangible assets	0.0	0.0	2.7	3.0	0.0	0.0	0.0
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	7.3	-0.3	5.9	-14.0	-2.5	8.3	11.2
Margin	3.5 %	-0.1 %	2.8 %	-7.1 %	-1.3 %	4.0 %	5.3 %
EBIT adj.	7.3	-0.3	5.9	-14.0	-2.5	8.3	11.2
Interest income	2.1	2.8	2.2	2.5	1.8	1.6	1.4
Interest expenses	1.9	1.4	1.8	2.6	0.3	0.3	0.3
Other financial income (loss)	-0.4	0.1	-0.3	-0.6	-0.7	-0.7	-0.7
EBT	7.1	1.3	5.9	-14.7	-1.7	8.9	11.6
Margin	3.4 %	0.6 %	2.8 %	-7.5 %	-0.9 %	4.3 %	5.5 %
Total taxes	2.4	0.4	4.2	0.4	-0.5	2.8	3.7
Net income from continuing operations	4.6	0.9	1.7	-15.1	-1.2	6.0	7.9
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	4.6	0.9	1.7	-15.1	-1.2	6.0	7.9
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	4.6	0.9	1.7	-15.2	-1.2	6.0	7.9
Margin	2.3 %	0.4 %	0.8 %	-7.7 %	-0.6 %	2.9 %	3.7 %
Number of shares, average	16.2	16.2	16.2	16.2	16.2	16.2	16.2
EPS	0.29	0.06	0.11	-0.94	-0.07	0.37	0.49
EPS adj.	0.29	0.06	0.11	-0.94	-0.07	0.37	0.49
*Adjustments made for:							

Guidance: Revenues EUR 198-201m, EBITDA EUR 17-18m (2021)


Financial Ratios

2017	2018	2019	2020	2021e	2022e	2023e
92.8 %	98.4 %	92.9 %	99.1 %	95.0 %	90.0 %	89.0 %
-15.3 x	n.a.	n.a.	n.a.	-38.8 x	n.a.	11.8 x
13.8 x	12.3 x	18.5 x	3.1 x	53.3 x	89.3 x	99.0 x
34.3 %	28.4 %	71.3 %	-3.0 %	32.0 %	32.0 %	32.0 %
41.7 %	54.1 %	28.4 %	0.0 %	0.0 %	39.6 %	40.1 %
170,431	165,358	165,992	152,436	152,612	154,108	155,619
	92.8 % -15.3 x 13.8 x 34.3 % 41.7 %	92.8 % 98.4 % -15.3 x n.a. 13.8 x 12.3 x 34.3 % 28.4 % 41.7 % 54.1 %	92.8 % 98.4 % 92.9 % -15.3 x n.a. n.a. 13.8 x 12.3 x 18.5 x 34.3 % 28.4 % 71.3 % 41.7 % 54.1 % 28.4 %	92.8 % 98.4 % 92.9 % 99.1 % -15.3 x n.a. n.a. n.a. 13.8 x 12.3 x 18.5 x 3.1 x 34.3 % 28.4 % 71.3 % -3.0 % 41.7 % 54.1 % 28.4 % 0.0 %	92.8 % 98.4 % 92.9 % 99.1 % 95.0 % -15.3 x n.a. n.a. n.a. -38.8 x 13.8 x 12.3 x 18.5 x 3.1 x 53.3 x 34.3 % 28.4 % 71.3 % -3.0 % 32.0 % 41.7 % 54.1 % 28.4 % 0.0 % 0.0 %	92.8 % 98.4 % 92.9 % 99.1 % 95.0 % 90.0 % -15.3 x n.a. n.a. n.a. -38.8 x n.a. 13.8 x 12.3 x 18.5 x 3.1 x 53.3 x 89.3 x 34.3 % 28.4 % 71.3 % -3.0 % 32.0 % 32.0 % 41.7 % 54.1 % 28.4 % 0.0 % 0.0 % 39.6 %

Sales, EBITDA in EUR m







Performance per Share



COMMENT Published 22.11.2021

5




Consolidated balance sheet


Consolidated balance sheet							
In EUR m	2017	2018	2019	2020	2021e	2022e	2023e
Assets							
Goodwill and other intangible assets	35.1	40.8	38.8	39.5	44.5	49.5	56.5
thereof other intangible assets	26.7	30.3	34.1	35.6	40.6	45.6	52.6
thereof Goodwill	8.5	10.4	4.6	3.8	3.8	3.8	3.8
Property, plant and equipment	31.8	29.9	29.2	24.9	21.4	18.9	17.4
Financial assets	11.6	13.4	18.1	16.3	16.3	16.3	16.3
Other long-term assets	0.0	0.0	11.2	0.0	0.0	0.0	0.0
Fixed assets	78.5	84.1	97.3	80.7	82.2	84.7	90.2
Inventories	10.6	11.2	12.4	11.5	11.8	12.1	12.5
Accounts receivable	19.5	19.0	18.1	18.1	18.1	18.6	19.2
Liquid assets	34.9	30.9	30.5	36.1	35.6	40.6	42.4
Other short-term assets	27.1	21.6	28.0	27.6	27.6	27.6	27.6
Current assets	92.1	82.7	89.0	93.3	93.0	99.0	101.7
Total Assets	170.6	166.7	186.3	174.0	175.2	183.6	191.8
Liabilities and shareholders' equity							
Subscribed capital	16.3	16.3	16.3	16.3	16.3	16.3	16.3
Capital reserve	34.8	34.7	34.7	34.3	34.3	34.3	34.3
Retained earnings	0.0	0.0	0.0	0.0	-36.9	-38.3	-34.5
Other equity components	-17.4	-17.7	-19.0	-36.9	-1.2	6.0	7.9
Shareholders' equity	33.7	33.3	32.0	13.7	12.5	18.3	24.0
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	33.7	33.3	32.0	13.7	12.5	18.3	24.0
Provisions	17.7	17.6	24.0	25.9	25.9	25.9	25.9
thereof provisions for pensions and similar obligations	16.5	16.2	20.6	20.5	20.5	20.5	20.5
Financial liabilities (total)	43.6	39.3	50.2	47.0	47.0	47.0	47.0
Short-term financial liabilities	0.4	0.2	4.1	3.7	3.7	3.7	3.7
Accounts payable	11.2	14.0	14.6	14.1	14.4	14.9	15.3
Other liabilities	64.5	62.6	65.5	73.3	75.4	77.5	79.6
Liabilities	137.0	133.4	154.3	160.3	162.7	165.2	167.8
Total liabilities and shareholders' equity	170.6	166.7	186.3	174.0	175.2	183.6	191.8

Financial Ratios

	2017	2018	2019	2020	2021e	2022e	2023e
Efficiency of Capital Employment							
Operating Assets Turnover	4.1 x	4.4 x	4.6 x	4.8 x	5.4 x	5.9 x	6.3 x
Capital Employed Turnover	3.5 x	3.5 x	2.9 x	4.3 x	4.5 x	4.6 x	4.3 x
ROA	5.9 %	1.1 %	1.8 %	-18.8 %	-1.4 %	7.1 %	8.8 %
Return on Capital							
ROCE (NOPAT)	7.7 %	n.a.	2.6 %	n.a.	n.a.	12.6 %	16.2 %
ROE	13.4 %	2.7 %	5.2 %	-66.3 %	-8.8 %	39.1 %	37.3 %
Adi. ROE	13.4 %	2.7 %	5.2 %	-66.3 %	-8.8 %	39.1 %	37.3 %
Balance sheet quality							
Net Debt	25.2	24.6	40.3	31.4	31.9	26.9	25.1
Net Financial Debt	8.6	8.4	19.7	10.9	11.4	6.3	4.5
Net Gearing	74.7 %	73.9 %	125.9 %	229.7 %	255.2 %	146.4 %	104.3 %
Net Fin. Debt / EBITDA	32.8 %	49.1 %	59.3 %	136.5 %	71.2 %	23.6 %	15.2 %
Book Value / Share	2.1	2.1	2.0	0.8	0.8	1.1	1.5
Book value per share ex intangibles	-0.1	-0.5	-0.4	-1.6	-2.0	-1.9	-2.0



Book Value per Share



WARBURG RESEARCH

6

Consolidated cash flow statement



In EUR m	2017	2018	2019	2020	2021e	2022e	2023e
Net income	4.6	0.9	1.7	-15.2	-1.2	6.0	7.9
Depreciation of fixed assets	19.1	17.3	24.7	18.9	18.5	18.5	18.5
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.0	0.0	2.7	3.0	0.0	0.0	0.0
Increase/decrease in long-term provisions	-0.5	-0.3	4.4	-0.1	0.0	0.0	0.0
Other non-cash income and expenses	0.0	2.0	0.0	0.0	2.0	2.0	2.0
Cash Flow before NWC change	23.2	19.9	33.5	6.7	19.3	26.5	28.4
Increase / decrease in inventory	0.6	-0.6	-1.2	0.8	-0.2	-0.4	-0.4
Increase / decrease in accounts receivable	-0.6	0.6	0.8	0.0	0.1	-0.5	-0.6
Increase / decrease in accounts payable	0.6	2.8	0.6	-0.4	0.3	0.4	0.4
Increase / decrease in other working capital positions	-2.5	1.5	-10.7	15.6	0.0	0.0	0.0
Increase / decrease in working capital (total)	-1.9	4.3	-10.4	16.0	0.1	-0.5	-0.5
Net cash provided by operating activities [1]	21.3	24.2	23.1	22.8	19.5	26.1	27.9
Investments in intangible assets	-6.9	-9.0	-13.8	-4.0	-5.0	-5.0	-7.0
Investments in property, plant and equipment	-8.6	-9.0	-6.5	-4.8	-15.0	-16.0	-17.0
Payments for acquisitions	0.0	-3.5	0.0	-2.2	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.3	-1.1	-0.3	0.0	0.0	0.0
Net cash provided by investing activities [2]	-15.5	-21.2	-21.4	-11.4	-20.0	-21.0	-24.0
Change in financial liabilities	4.5	-4.3	11.0	-3.3	0.0	0.0	0.0
Dividends paid	-0.8	-1.9	-0.5	-0.5	0.0	0.0	-2.1
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	-2.6	-0.2	-15.2	-1.9	0.0	0.0	0.0
Net cash provided by financing activities [3]	1.1	-6.4	-4.7	-5.7	0.0	0.0	-2.1
Change in liquid funds [1]+[2]+[3]	6.9	-3.5	-3.0	5.1	-0.5	5.1	1.8
Effects of exchange-rate changes on cash	-1.4	0.5	0.0	-1.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	24.2	21.2	18.1	22.2	21.7	26.7	28.5

Financial Ratios


	2017	2018	2019	2020	2021e	2022e	2023e
Cash Flow							
FCF	5.8	6.1	2.8	13.9	-0.5	5.1	3.9
Free Cash Flow / Sales	2.8 %	3.0 %	1.3 %	7.1 %	-0.3 %	2.5 %	1.8 %
Free Cash Flow Potential	12.3	1.8	9.7	-1.1	9.7	17.0	18.8
Free Cash Flow / Net Profit	124.3 %	685.7 %	163.8 %	-91.7 %	46.8 %	84.1 %	49.6 %
Interest Received / Avg. Cash	6.9 %	8.7 %	7.2 %	7.4 %	5.0 %	4.2 %	3.4 %
Interest Paid / Avg. Debt	4.7 %	3.4 %	4.0 %	5.2 %	0.6 %	0.6 %	0.6 %
Management of Funds							
Investment ratio	7.5 %	8.8 %	9.7 %	4.5 %	10.0 %	10.2 %	11.3 %
Maint. Capex / Sales	2.3 %	2.4 %	2.3 %	2.5 %	2.4 %	2.3 %	2.3 %
Capex / Dep	81.2 %	104.2 %	73.9 %	40.4 %	108.1 %	113.5 %	129.7 %
Avg. Working Capital / Sales	9.3 %	8.6 %	7.7 %	8.0 %	7.7 %	7.6 %	7.6 %
Trade Debtors / Trade Creditors	174.2 %	135.7 %	124.4 %	128.3 %	125.2 %	125.2 %	125.2 %
Inventory Turnover	9.7 x	9.1 x	8.2 x	8.2 x	8.7 x	8.1 x	8.1 x
Receivables collection period (days)	35	34	32	34	33	33	33
Payables payment period (days)	40	50	52	55	52	55	55
Cash conversion cycle (Days)	32	24	24	24	23	23	23

Free Cash Flow Generation

CAPEX and Cash Flow in EUR m



Working Capital



COMMENT

Published 22.11.2021

7



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <u>http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</u>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).



SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The **Warburg ESG Risk Score** is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.

-4-



Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.)

KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.

3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.

4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.

5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the management of a consortium for an issue in
 -2- the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- -3- Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.

MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of

- confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment** recommendation with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Francotyp-Postalia	5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE000FPH9000.htm



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.		
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.		
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.		
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.		

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING


Rating	Number of stocks	% of Universe
Buy	154	71
Hold	56	26
Sell	5	2
Rating suspended	3	1
Total	218	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	49	83
Hold	8	14
Sell	0	0
Rating suspended	2	3
Total	59	100

PRICE AND RATING HISTORY FRANCOTYP-POSTALIA AS OF 22.11.2021



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

EQUITIES

Matthias Rode Head of Equities

RESEARCH

Michael Heider Head of Research Henner Rüschmeier Head of Research Stefan Augustin Cap. Goods, Engineering Jan Bauer Renewables Jonas Blum Telco, Media, Construction **Christian Cohrs** Industrials & Transportation Dr. Christian Ehmann BioTech. Life Science Felix Ellmann Software, IT Jörg Philipp Frey Retail, Consumer Goods Marius Fuhrberg **Financial Services** Mustafa Hidir Automobiles, Car Suppliers Philipp Kaiser Real Estate

INSTITUTIONAL EQUITY SALES

+49 40 309537-280 mheider@warburg-research.com +49 40 309537-270 hrueschmeier@warburg-research.com +49 40 309537-168 saugustin@warburg-research.com +49 40 309537-155 jbauer@warburg-research.com +49 40 309537-240 jblum@warburg-research.com +49 40 309537-175 ccohrs@warburg-research.com +49 40 309537-167 cehmann@warburg-research.com +49 40 309537-120 fellmann@warburg-research.com +49 40 309537-258 jfrey@warburg-research.com +49 40 309537-185 mfuhrberg@warburg-research.com +49 40 309537-230 mhidir@warburg-research.com +49 40 309537-260 pkaiser@warburg-research.com

+49 40 3282-2678

mrode@mmwarburg.com

+49 40 3282-2660 mniemann@mmwarburg.com +49 69 5050-7400 kschilling@mmwarburg.com +49 40 3282-2665 tbeckmann@mmwarburg.com +49 69 5050-7411 lbogdanova@mmwarburg.com +49 69 5050-7415 jbuchmueller@mmwarburg.com +49 40 3282-2669 aeschweiler@mmwarburg.com +49 40 3282-2696 mfritsch@mmwarburg.com

SALES TRADING

Marc Niemann

Klaus Schilling

Tim Beckmann

Lea Bogdanova

Jens Buchmüller

Scandinavia, Austria

United Kingdom, Ireland

Alexander Eschweiler

Germany, Luxembourg

Matthias Fritsch

United Kingdom

United Kingdom

Head of Equity Sales. Germany

Head of Equity Sales, Germany

 Oliver Merckel
 +49 40 3282-2634

 Head of Sales Trading
 omerckel@mmwarburg.com

 Elyaz Dust
 +49 40 3282-2702

 Sales Trading
 edust@mmwarburg.com

 Michael Ilgenstein
 +49 40 3282-2700

 Sales Trading
 edust@mmwarburg.com

 Michael Ilgenstein
 +49 40 3282-2700

 Sales Trading
 milgenstein@mmwarburg.com

MACRO RESEARCH

 Carsten Klude
 +49 40 3282-2572 cklude@mmwarburg.com
 Dr. Christian Jasperneite Investment Strategy

 Our research can be found under:
 Investment Strategy

 Warburg Research
 research.mmwarburg.com/en/index.html
 Refinitiv

 Bloomberg
 RESP MMWA GO
 Capital IQ

 FactSet
 www.factset.com
 Investment Strategy

For access please contact:

Andrea Schaper Sales Assistance +49 40 3282-2632 aschaper@mmwarburg.com Kerstin Muthig Sales Assistance

Thilo Kleibauer Retail, Consumer Goods Eggert Kuls Engineering Andreas Pläsier Banks, Financial Services Malte Schaumann Technology **Oliver Schwarz** Chemicals, Agriculture Simon Stippig Real Estate Cansu Tatar Cap. Goods. Engineering Marc-René Tonn Automobiles, Car Suppliers Robert-Jan van der Horst Technology Andreas Wolf Software, IT

Maximilian Martin

Christopher Seedorf

Austria, Poland

Sophie Hauer Roadshow/Marketing

Juliane Niemann

Roadshow/Marketing

Marcel Magiera

Bastian Quast

Sales Trading

Sales Trading

Sales Trading

Jörg Treptow

Switzerland

+49 40 309537-257 tkleibauer@warburg-research.com +49 40 309537-256 ekuls@warburg-research.com +49 40 309537-246 aplaesier@warburg-research.com +49 40 309537-170 mschaumann@warburg-research.com +49 40 309537-250 oschwarz@warburg-research.com +49 40 309537-265 sstippig@warburg-research.com +49 40 309537-248 ctatar@warburg-research.com +49 40 309537-259 mtonn@warburg-research.com +49 40 309537-290 rvanderhorst@warburg-research.com +49 40 309537-140 awolf@warburg-research.com

> +49 69 5050-7413 mmartin@mmwarburg.com +49 40 3282-2695 cseedorf@mmwarburg.com

> +49 69 5050-7417 shauer@mmwarburg.com +49 40 3282-2694 jniemann@mmwarburg.com

+49 40 3282-2662 mmagiera@mmwarburg.com +49 40 3282-2701 bquast@mmwarburg.com +49 40 3282-2658 jtreptow@mmwarburg.com

+49 40 3282-2439 cjasperneite@mmwarburg.com

> www.refinitiv.com www.capitaliq.com

+49 40 3282-2703 kmuthig@mmwarburg.com

